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INTRODUCTION 
  Over 200 years have elapsed since William Heberden’s[1768],one sentence 
description of angina pectoris before the Royal college of Physicians- 
 “Those , whose are afflicted with it, are seized, while they are  walking, and 
more particularly when they walk soon after eating, with a painful and most 
disagreeable sensation in the breast, which seems as if it  would take their life away, if 
it were to increase or to continue; the moment they stand still, all this uneasiness 
vanishes”, this has been repeatedly confirmed but seldom improved upon. 
              Until 1921, it was believed that acute myocardial infarction was uniformly 
fatal. It was James Herrick, a Chicago physician, who first described survival after 
infarction in an article that appeared in the journal of the American Medical 
Association in 1921. 
             In subsequent years, as the understanding of the pathophysiological principles 
of myocardial infarction begin to grow, as did the treatment modalities and the 
prognosis began to improve. Despite impressive studies in diagnosis and management 
over the past 3 decades, AMI continues to be a major public health problem in 
industrialized world and is becoming an increasingly important problem in developing 
countries. 
Modern ‘reperfusion era’ of coronary care was introduced by intracoronary and 
intravenous thrombolysis , increased use of aspirin and development of PTCA and 
intracoronary stents for AMI. The transition of coronary care from 
  
pathophysiologically based decision making to “evidence-based decision” making is 
supported by the rich database of clinical trials and meta-analysis. 
 If subjects at high risk of sudden cardiac death were easily identifiable, then 
targeted therapy might be able to reduce cardiac deaths. Unfortunately, we do not yet 
possess an applicable screening method for this purpose. Techniques exists for this 
such as signal-averaged electrocardiography, T-wave alternans and heart rate 
variability, but they have variable success and tend to require specialized equipment, 
making them difficult in routine practice. Another possibility is QT interval analysis, 
which stems from the fact that individuals with long QT syndromes are known to be at 
high risk of sudden cardiac death.  
        Taking this principle one step further, it is possible that the variation of QT 
intervals within an ECG in more routine patients may also contain prognostic 
information. ‘QT interval dispersion’ is at present undergoing vigorous assessment for 
this purpose. Several years ago, Campbell et al –1  enthusiastically called it the “ 
electrophysiological Holy Grail ”. The number of studies indexed in the Medline on 
QT dispersion has risen 34-fold since its description in 1990. 
           In this study, an attempt has been made to find out QT dispersion in healthy 
individuals and patients of Acute Myocardial Infarction and to find out correlation, if 
any, between QT dispersion and the incidence of ventricular arrhythmias in acute 
myocardial infarction.   
 
  
 
 
AIMS OF THE STUDY 
This prospectively designed study aimed to examine  
1. QT dispersion in normal individuals. 
2. QT dispersion in AMI. 
3. QT dispersion and site of infarct. 
4. QT dispersion and reperfusion therapy. 
5. QT dispersion, ventricular arrhythmias and mortality in AMI. 
 
 
    
 
 
 
 
  
REVIEW OF LITERATURE 
HISTORICAL ASPECTS:    
         A Dutch physician, William Einthoven [1860-1927] introduced the ECG 
‘PQRST’ designations we use today, and the QT interval has been known since 1887 
to represent ventricular electrical activities-4 . One hundred years later, a group from 
Newcastle –5  proposed that the interlead QT interval differences within a 12 lead ECG 
might reflect regional differences in myocardial refractoriness, and that this might 
predict cardiac dysrhythmias. Animal –6 and human –7 studies supported this 
observation. Using epicardial monophasic action potentials in isolated rabbit hearts, 
Zabel et al –8 correlated this QT interval variation with the degree of homogeneity in 
ventricular repolarisation. This correlation would suggest that QT dispersion is at best 
a surrogate marker, rather than an accurate measure of ventricular repolarisation . In 
reality, the repolarisation process is nondipolar and hence there is only one end-of-
repolarisation and the onset of repolarisation is nearer to the T-wave peak within a 
surface ECG-9. 
 The view that sudden obstruction of a coronary artery was incompatible with 
life for more than few minutes persisted even in twentieth century. The modern era 
can be said to have begun with the autopsy studies of ‘Herrick’, who concluded in 
1912, that the clinical syndrome of myocardial infarction results from the acute 
thrombolytic occlusion of coronary arteries, with resulting down stream necrosis-10. 
His statement , “ Death results in nearly all these cases, yet it may be delayed for 
  
many days. More than this, there is, as has been shown by reference to experimental 
work, no intrinsic reason why some patients with obstruction may not recover-10.  
          Since then management of myocardial infarction has undergone numerous 
changes with progressive reduction in mortality from the pre-ICU era to ICU era to 
the recent thrombolytic era. 
EPIDEMIOLOGY 
       Acute myocardial infarction is one of the most common diagnosis in 
hospitalized patients in industrialized countries.  
         Approximately 1.1 million AMI occur each year in U.S. and mortality is upto 
30%. 
INDIAN SCENARIO: 
 While CAD has been halved in west in the past 50 yrs, rates have doubled in 
India. 
 CAD prevalence in Urban India – 10% 
                                       Rural India – 5% 12-14. 
 
 
 
  
PECULIARITIES IN INDIAN CAD: 
1. Extreme prematurity. CAD mortality in Indians< 30 yrs of age is 3 fold 
higher than whites15. 
2. Women have rates similar to men despite smoking being uncommon in 
Indian women16. 
3. Higher prevalence of glucose intolerance and lower prevalence of 
conventional coronary risk factors17. 
 Although atherosclerosis is the most common cause of luminal narrowing in 
coronary artery disease, multiple non-atherosclerotic causes account for 4-7% of 
causes of acute MI18-19. 
PATHOGENESIS AND PATHOLOGY 
         Coronary Atherosclerosis[AS] in the form of stenosing plaques is the major 
etiologic factor behind various clinical syndromes of IHD. Only in a small minority 
is non-atherosclerotic lesion like emboli, vasculitis,dissection may be the cause. 
          Stenosis caused by atheromatous plaque may be eccentric or concentric20. 
Eccentric plaque causes total variation in lumen leading to variable luminal stenosis. 
Concentric plaque has fixed stenosis21. 
            Fatty streaks – earliest lesion in AS can be found in coronaries of children22 . 
With increasing age fatty streaks evolve into fibromuscular plaques. Platelet 
adherence, platelet aggregation and release of smooth muscle growth factors, causes 
embryonic atherosclerotic plaque to increase in size.  
  
           Smooth muscle and fibrous tissue growth factors are released from disturbed 
endothelium and macrophages derived from adherent monocytes. Abnormal lipid 
transport from arterial lumen, necrosis and calcification occur in AS plaque. 
           Clinical presentation and prognosis of coronary AS depend on the plaque 
type rather than the size23. Type IV and Va plaques are plaques prone for disruption. 
PLAQUE MORPHOLOGY24: 
 Stable plaque – stable angina 
• Small lipid pool. 
• Thick fibrous cap. 
• High grade stenosis. 
• Not at bend or branch. 
 
 
  
 
  
 Unstable / vulnerable plaque 
• Large lipid pool. 
• Younger, less stenotic. 
• Located at branch points. 
• Thin plaque cap. 
• Numerous macrophages. 
• Paucity of smooth muscle cells in cap. 
MECHANISM OF THROMBOSIS:  
Three forms of vascular injury: IP et al25. 
1. Type I – Endothelial dysfunction. 
2. Type II – Endothelial denudation and intimal damage with intact internal 
elastic lamina. 
3. Type III – Endothelial denudation and damage of both intima and media.  
         Rupture of plaque is a function of internal plaque changes[Intrinsic factor] and 
external stresses[Triggers] 
     Internal – plaque vulnerability. 
External – systemic Triggers-     Exercise 
                                                    Cigarette smoking 
                                                     BP swings 
  
                                                      Epinephrine 
                                                      Emotions 
                                                      Assuming erect posture 
                                                      Cold exposures. 
Local Triggers                               Infection 
                                                       Inflammation26. 
           Platelet activation with release of thromboxane A2 is an accompanying 
phenomenon – Hrish et al27.   
BIOCHEMISTRY AND PATHOLOGY 
PATHOLOGY: 
             Persistent myocardial ischemia leads to infarction with wave front 
progressing from subendocardium to sub-epicardium. 
Myocyte necrosis – 3 types 
1. Coagulation necrosis – “Atonic Death” contractile ability of myocyte 
is lost. 
2. Contraction band necrosis – “Tetanic Death” Occurs at periphery of 
infarct.  Hyper contractile state. 
  
3. Colliquative myocytolysis – “Failing Death” Vacuolated myocyte, 
loose their function. 
               HISTOLOGICAL CHANGES: 
¾ P.M.N.s invade tissue                           6 – 8 hours. 
¾ Cross structures of myocyte lost           24 hours 
¾ Sarcoplasm assumes granular appearance 
¾ Macrophages infiltration in lesion         48 – 72 hours 
¾ Neocapillarization begins with                
  fibroblast and capillaries                 3 – 5 days 
¾ Collagen deposition starts                        7 – 10 days 
¾ Leads to fibrous scar. 
 
 
 
 
 
 
 
  
BIOCHEMISTRY AND ULTRASTRUCTURE: 
       20 – 40 minutes of myocardial ischemia leads to irreversible cellular 
derangement. 
¾ Sarcolemmal injury is the critical event determining the irreversibility of 
cellular damage, leads to leakage of essential enzymes out of cell and 
entrance of calcium and water into the cell. 
¾ Mitochondria swollen with amorphous matrix. 
¾ High energy phosphates[ATP] rapidly depleted28. 
¾ Anaerobic glycolysis employed initially with glucose as substrate and large 
amount of intracellular lactate accumulation29. 
¾ Arachidonic acid liberation - FFA ↑. 
¾ O2 derived free radicals and intracellular calcium overload, ‘chokes’ the 
mitochondria30,31. 
CIRCADIAN VARIATION:   
         AMI has marked circadian periodicity with peak prevalence between 6A.M. 
and noon. There is 3- fold increase in frequency of infarction at peak 9.00 A.M.32. This 
is due to diurnal variation in thrombotic tendencies – platelet aggregability33, circadian 
variations in blood pressure34 and sympathetic nervous system35. 
 
 
  
RISK FACTORS FOR AS/ AMI    
NON-MODIFIABLE RISK FACTOR: 
9 Age. 
9 Male gender. 
9 Low socio economic status. 
9 Family history of early onset CAD. 
MODIFIABLE RISK FACTORS: 
CATEGORY I: 
9 LDL cholesterol ↑ 
9 HDL cholesterol ↓ 
9 Atherogenic diet 
9 Cigarette smoking 
9 Hypertension 
9 LV hypertrophy 
9 Thrombogenic factors. 
CATEGORY II: 
9 Diabetes mellitus 
9 Physical inactivity 
9 Triglycerides 
9 Obesity 
 
  
CATEGORY III:   
9 Phycosocial factors 
9 Lipoprotein(a) 
9 Homocysteine 
9 Inflammation marker – particularly CRP 
9 No alcohol consumption 
9 Oxidative stress 
9 Post menopausal status. 
INDIAN SCENARIO37:   
 Higher prevalence of Diabetes , Insulin resistance syndromes, central obesity. 
 Lower prevalence of conventional risk factors like Hypertension, Obesity, 
Cigarette smoking, high cholesterol.  
 Emerging newer risk factors like high lipoprotein(a), homocysteine, Apo B, 
triglycerides, fibrinogen, PAI-I. 
 Low HDL and HDL2b. 
 Small dense LDL.  
HISTORY AND PHYSICAL EXAMINATION FOR AMI 
          Classic symptoms – chest discomfort which is retrosternal (or) precordial, 
described as pressure, aching, burning, crushing, squeezing, heavy, swelling or 
bursting in quality. Radiation to arm (medial aspect), neck or jaw, back etc.38. 
  Skip areas with retrosternal pain common. 
  
 Approximately 23% of MI go unrecognized due to atypical symptoms or 
presentations39. 
o Nausea or vomiting / Indigestion(common with IWMI) 
o Atypical location of pain – arm, back, jaw, occiput 
o Profound fatigue of rapid onset 
o Cerebral or peripheral embolus 
o Pulmonary edema of sudden onset 
o Mental obtundation 
o Severe ventricular dysrhythmias 
o Painless myocardial infarction is common in elderly >60 yrs and 
diabetics. 
CLINICAL EXAMINATION:  
          Findings vary from normal to shock from low cardiac output. 
1. Rhythm: varies from regular with tachycardia and a few extrasystoles to 
multiple ectopics, VT, and VF. Atrial fibrillation is usually unimportant. 
Acute MI involving inferior wall is often associated with transient hypo 
tension and sinus bradycardia. 
            Bezold Jarish Reflex – Bradycardia 
                                                   Hypo tension 
                                                   Nausea / vomiting. 
  
stimulation of inhibitory cardiac receptors in the 
inferoposterior wall of LV. 
2. Blood pressure is often elevated at first (from emotion) and later falls. 
3. Jugular venous pressure is normal, unless there is complicating Heart failure. 
PRECORDIAL PALPATION:  
 Diffuse apical impulse 
 Dyskinesia – paradoxical bulge in late systole. 
 Palpable S4 
 Paradoxical splitting, rarely due to severe LV dysfunction. 
AUSCULTATION:   
 Muffled heart sounds 
 Muffled S1 common in IWMI due to prolonged PR interval. 
 S4 – 98% of cases of AMI40. 
 S3 – 15 – 20% of cases of AMI41. 
 Pericardial rub 
 Crescendo – decrescendo mid systolic murmur due to ischemia of papillary 
muscles. 
 Mitral regurgitation murmur. 
 PSM due to ventricular septal rupture. 
EXAMINATION OF LUNG FIELDS: 
     Pulmonary congestion occur in 30 – 40 % of uncomplicated MI. 
  
KILLIP AND KIMBALL CLASSIFICATION:     
 Class I – No pulmonary rales or S3 
 Class II – Bibasilar rales that persist after coughing. 
                        < 50 % of lung fields or S3 
 Class III – Rales over one-half of the lung fields bilaterally with radiographic 
evidence for pulmonary edema ( > 50 % of lung fields) 
 Class IV – Cardiogenic shock.  
FORRESTER STAGING:   
 I   -  Normal hemodynamics. 
 II – Hyperkinetic state. 
 III – Hypovolemia 
 IV  - LV failure – A. Mild 
                               B. Severe 
 V  - Cardiogenic shock. 
 VI – Shock due to RVMI. 
 
 
 
  
DIAGNOSIS OF MYOCARDIAL INFARCTION:   
Triad of       
i. Chest pain 
ii. Electrocardiographic changes 
iii. Plasma enzyme activity.  
ELECTROCARDIOGRAPHIC CHANGES OF AMI: 
       The ECG is a cornerstone in the diagnosis of acute and chronic heart disease. 
In AMI, typically there are changes in the S-T segments, T wave and QRS 
complexes. It is only the QRS changes which are diagnostic of myocardial 
infarction. 
THE QRS CHANGES OF AMI:    
       Two QRS abnormalities may be indicative of myocardial infarction.  
They are 
1. Localized, inappropriately low, R wave voltage. 
2. Abnormal Q waves.  
      The development of a negative wave ( a Q wave) and the reduction in size of 
the positive wave are the result of loss of positivity from necrosis of myocardium. 
 
  
LOSS OF R WAVE VOLTAGE: 
 If infarction involves only part of the thickness of the myocardial wall the QRS 
complexes recorded from the area of the infarction will show a reduction on R wave 
voltage. 
ABNORMAL Q WAVES AND QS COMPLEXES:   
       When infarction involves the full thickness of the myocardium there will be 
total loss of R waves in leads overlying the infarcted zone i .e. the waves will be 
entirely negative (QS complexes). These negative waves are the result of 
depolarization of the posterior wall of the ventricles traveling from the endocardium 
to epicardium (and therefore away from the precordial leads).  The four possible 
QRS changes which may indicate the presence of myocardial infarction are as 
follows:  
1. Reduced R wave voltage ( where it can confidently be ascertained that 
this has occurred). 
2. Abnormal Q waves without any conclusive evidence of R wave 
reduction. 
3. Abnormal Q waves with evidence of reduced R wave voltage. 
4. Abnormal QS complexes. 
      A normal q wave is not > one-quarter of the height of the ensuing R wave and is 
< 0.04 s in duration. Abnormal Q waves have a depth > 25 % of the height of the 
ensuing R wave, or a duration ⊇ 0.04 s. 
  
THE ST-T SEGMENT CHANGES OF INFARCTION:  
         In the early stages of infarction S-T segment elevation usually occurs and may 
occasionally be dramatic in degree. Abnormal S-T segment elevation occurs in leads 
facing an area of transmural infarction. Leads looking at the heart from the opposite 
aspect will show ‘reciprocal’ S-T segment depression at a time when there is 
‘primary’ S-T segment elevation in the leads related to the infarction. The precordial 
leads and lead I and aVL on the one hand and the inferior limb leads ( leads II, III, 
and aVF) on the other hand are mutually reciprocal in this aspect.    
THE T WAVE CHANGES OF INFARCTION:   
          A whole variety of non-specific T wave changes may occur in association 
with myocardial infarction. These include flattening of the T waves, inversion of T 
waves and abnormally tall T waves. Widespread deep symmetrical T wave inversion, 
whilst still, strictly speaking a non-specific change, suggests subendocardial 
infarction.   
 
 
 
 
 
  
THE QT INTERVAL:   
        
        The interval from the beginning of QRS complex to the end of T wave is called 
QT interval. It is sum total of the time taken by depolarization and repolarisation  of 
the ventricles. The total electrical activity of the ventricles is reflected in QT interval. 
It is variable in different parts of the ventricles, but the QT interval measured on the 
surface electrocardiogram represents the total longest interval of QT. 
      The QT interval shortens with tachycardia and lengthens during bradycardia. In 
other words, the QT changes with change in RR interval; the latter represents the 
heart rate. Therefore, for meaningful expression, the QT must be corrected for heart 
rate called corrected QT (QTc) interval. The QT interval is corrected for what it 
would be at a rate of 60 bpm. 
           Corrected QT ( QTc)            =    QT interval in sec  /  √RR interval in sec 
            By Bazett’s formula. 
 
  
MEASUREMENT OF QT:  
          It is measured in seconds from the beginning of Q wave to the end of the T 
wave. It is difficult to measure sometimes because it is difficult to delineate the 
beginning and end of the interval. It is  customary to measure it in the lead having ‘q’ 
wave such as leads I, II, aVL, V5 or V6 so as to avoid error of ignoring the initial 
part of QRS. Similarly, the end point of T wave may be difficult to find out, but if U 
wave is present, then it becomes easy as the dip between T and U wave becomes the 
end point of T wave. 
      Sleep prolonged the QT interval by 18 ms at a heart rate of 60 beats / min and 
by 2 ms at a heart rate of 50 beats / min compared with the waking state42. This 
diurnal variation is thought to be related to autonomic tone. 
CAUSES OF LONG QT INTERVAL:   
¾ Physiological – during sleep 
¾ Congenital-prolonged QT syndrome – The Jervell-Lange-Nielsen 
syndrome and Romano-Ward syndrome. 
¾ Acquired – Hypocalcemia 
¾ Acute myocarditis 
¾ Acute myocardial infarction 
¾ Quinine, Quinidine and Procainamide effect 
¾ Antidepressants (Tricyclic and Tetracyclics) 
¾ Head injury with intracerebral bleed 
¾ Hypothermia 
  
¾ Idiopathic hypertropic cardiomyopathy 
¾ Advanced or complete heart block 
¾ Ventricular tachycardia – Torsade de pointes. 
SHORT QT INTERVAL:  
¾ Digitalis effect 
¾ Hyperthermia 
¾ Vagal stimulation 
¾ Hypercalcemia. 
QT DISPERSION( QT d):    
           Day et al43 first proposed that interlead variability of QT interval in 12-lead 
electrocardiogram – QT dispersion [ defined as the difference between maximum 
and minimum QT interval duration] reflects dispersion of ventricular recovery time. 
           Theoretically the QT value should be the same but differences occur because 
of different projections of the ventricular complex on the limb axis in different leads. 
For instance, when the vectors are perpendicular to the QRST axis an isoelectric 
segment may be recorded at the onset of the QRS complex, at the end of the T wave 
thereby causing artificial shortening of the QT interval. In the precordial leads 
differences in the QT interval may be due to differences in the repolarisation 
duration at the site facing the recording electrodes. The latter factors probably 
account for most of the so called QT dispersion. 
  
         The QT interval is measured from the beginning of QRS to the end of T wave 
(i.e. return to the TP baseline). If U waves are present, then QT interval is measured 
to the nadir of the curve between the T and the U waves. For calculation of QT d, 3 
consecutive cycles are measured in each lead and the mean of these 3 cycles is taken 
as mean QT c of that lead. The QT may be corrected by Bazett’s formula. The mean 
normal QTcd is 45±15 ms. 
CLINICAL CONDITIONS ASSOCIATED WITH WIDE QTd INTERVAL:  
¾ Congenital or acquired prolonged QT syndrome 
¾ Hypertropic cardiomyopathy 
¾ Mitral valve prolapse 
¾ Coronary artery disease. 
CLINICAL SIGNIFICANCE: 
¾ QT d is believed to be a measure of electrical inhomogenity in the heart that 
decreases an individual’s threshold for ventricular arrhythmias, hence 
greater the QTd , greater is the chance to develop an arrhythmia. 
¾ Heart rate, reflex vagal activity and cardiac afterload physiologically alter 
the QT dispersion. 
¾ A significant QT dispersion was found both in patients with congenital and 
acquired long QT intervals, which is presumed to be the cause of Torsade-
de-pointes in these conditions. 
¾ Certain antiarrhythmic drugs decrease the QT dispersion hence, QT 
dispersion may be used to evaluate the efficacy of the drug. 
  
¾ Practical utility as a marker of acute ischemia with atrial pacing. 
PLASMA MARKERS OF MI:  
           As the myocyte become necrotic, the integrity of the sarcolemmal membrane 
is compromised and intracellular macromolecules ( cardiac markers) begin to diffuse 
into the cardiac interstitium and ultimately into the microvascular and lymphatics in 
the region of the infarct. Molecular markers used or proposed – for use in the 
diagnosis of Acute Myocardial Infarction44.  
Marker Time to 
initial 
elevation(hrs) 
Mean 
time to 
peak(hrs) 
Time to 
return to 
normal(hrs) 
Sampling 
schedule 
HFABP 
heart fatty 
acid 
binding 
proteins 
1 – 5 5 – 10 24 On 
presentation,then 
4 hrs later 
Myoglobin 1 – 4 6 – 7  24 1 – 2 hrs after 
chest pain 
MLC 
(Myosin 
Light 
Chain) 
6 – 12  2 – 4 
days 
6 – 12 days 12 hrs after chest 
pain 
cTn I ( 
Troponin 
I) 
3 – 12  24 hrs 5 – 10 days 12 hrs after chest 
pain 
c Tn T 
(Troponin 
T) 
3 – 12  12 hrs – 
2 days 
5 – 14 days  12 hrs after chest 
pain 
MB – CK 3 – 12 24 48 – 72 hrs Every 12 hrs × 3 
MB – CK 
tissue 
isoform 
2 – 6 18  - 60 – 90 mins 
after chest pain 
Enolase 6 – 10  24  48 Every 12 hrs×3 
LDH 10 24 – 48  10 – 14 
days 
24 hrs after chest 
pain 
MHC ( 
Myosin 
48 5 – 6 
days 
14 days  After 2 days of 
chest pain 
  
Heavy 
Chain) 
ENZYMATIC CRITERIA FOR DIAGNOSIS OF MI45:   
¾ Serial increase, then decrease of plasma MB-CK, with a change > 25 % 
between any 2 values 
¾ MB-CK >10 – 13 U/L or > 5 % of total CK activity. 
¾ Increase in MB-CK activity > 50% between any 2 samples, separated by at 
least 4 hrs. 
¾ If only a single sample available, MB-CK elevation > 2 fold. 
¾ Beyond 72 hrs, an elevation of Troponin T or I or LDH1>LDH2. 
Early diagnosis of MI is offered by MB-CK subforms and Myoglobin of which MB-
CK subform are most specific. 
¾ Absolute level of MB-CK2  isoform greater than 1.0 U/L within 4 – 6 
hrs of MI. 
¾ CK-MB2/ CK-MB1 greater than 2.5 ( within 4 – 6 hrs of MI). 91 % 
specificity and sensitivity46. 
CK ISOENZYMES:  
¾ 15 % of CK in the myocardium is CK-MB, which provides sensitivity and 
specificity as a marker. 
¾ CK-MB mass/ CK activity >2.5 indicates myocardial rather than skeletal 
muscle as a source of CK-MB. 
  
TROPONINS: 
¾ Cardiac Troponins are very specific for the myocardial injury. Normal 
plasma value for Troponin are near 0 and hence they are very sensitive 
also. 
¾ Troponins are not elevated in CRF. 
 
DIAGNOSIS OF RE-INFARCTION: 
        Secondary rise in CK-MB, 36 – 48 hrs after onset of symptoms, ⊇ 50 % above 
the preceding baseline. 
UPPER LIMIT OF NORMAL FOR MARKERS45:  
 Myoglobin                85ng/ml 
 CK-MB                     9 IU/ L 
 CK-MB2                    1.0 U/L 
 CK-MB2/CK-MB1     ⊇2.5 
 Troponin T                 0.1ng/ml 
 Troponin I                   1.5ng/ml 
OTHER BIOCHEMICAL ALTERATIONS: 
 Lipoprotein fractions are relatively unchanged in initial 1 – 2 days but 
decrease significantly over subsequent days and weeks. Hence lipid 
measurements are done in 24 to 48 hrs or 6 – 8 weeks later48. 
  
 WBC count show mild increase reaching peak in 3 – 5 days. 
 Erythrocyte sedimentation rate – maximum in the second week. 
IMAGING TECHNIQUE:  
CHEST ROENTGENOGRAM: 
          Amidst excluding other causes of chest pain such as pneumothorax, 
pulmonary infarction with effusion, aortic dissection, skeletal fractures, presence of 
pulmonary edema and increased heart size, a group of patient at high risk49. 
ECHOCARDIOGRAPHY: 
     Assessing patients with non-diagnostic ECG’s. Presence of regional wall 
motion abnormalities provides strong supportive evidence of acute coronary 
syndrome, generally transmural or Q – wave Myocardial Infarction50,51. 
RADIONUCLIDE ASSAY:  
        Role in certain patients with RVMI by showing localized contractile 
abnormalities, (or) 99mTc – pyrophosphate uptake52. Infarction not diagnosed by 
standard means, detection of residual ischemia, infarct size, hibernating myocardium, 
ventricular function are other indications. 
MANAGEMENT STRTEGIES:   
 PREHOSPITAL CARE is being increasingly stressed to achieve a further 
substantial decrease in the mortality rate, since 40 – 65 % of deaths, from AMI occur 
  
within an hour of onset of symptoms, prior to arrival to hospital , most commonly 
due to ventricular arrhythmias53, 54. 
STRATEGIES:  
 Education of patients for recognition of symptoms and call for 
help. 
 Role of paramedics in recognition and treating life threatening 
arrhythmias. 
 Pre-hospital thrombolysis – Alteplase for this purpose. 
HOSPITAL MANAGEMENT:   
DIAGNOSIS AND RISK STRATIFICATION: 
 Age, ECG with more number of leads showing ST changes, Q waves, 
prolonged chest pain. 
 SBP < 100 mm Hg and Bibasilar rales indicate high risk. 
 Killip classification is useful. 
 
 
 
 
 
  
ECG OF A PATIENT WITH INFERIOR WALL MI 
 
 
INITIAL MANAGEMENT: 
OXYGEN ADMINISTRATION: 
         Hypoxemia is common due to V.P. mismatch. Oxygen administration is 
reported to decrease ST segment elevation in anterior myocardial infarction55. 
Supplemental oxygen (2 – 4L/ min) for all cases of uncomplicated myocardial 
infarction with SaO2 > 90 % after 2 – 3 hrs and extended for those with onset 
pulmonary congestion and desaturation56. 
 
  
ANALGESIA:  
      To reduce anxiety / pain relief thereby reduce oxygen demand. Narcotics – 
Morphine (2 – 4 mg). Caution needed in Inferior infarct complicated by RVMI57. 
Nitrates – sublingual Nitroglycerine – 0.4mg doses upto 3 doses on 5 minutes 
intervals58. Decreases oxygen demand. Increases oxygen supply. Caution in Inferior 
infarct associated with RVMI. 
BETA BLOCKERS:  
¾ Pain  relief 
¾ Reduce frequency of progression of threatened infarction to complete 
infarction. 
¾ Reduce life threatening arrhythmias 
¾ Metoprolol – 5 mg every 2 – 5 minutes for total of 3 doses. Oral dose 50 
mg 15 minutes after last IV dose, then 50 mg 6 hrly for 48 hrs, then 100 
mg every 12h56. 
ASPIRIN: 
         160 – 325 mg of non-enteric coated chewable aspirin. Inhibits platelet COX – 
irreversibly and blocks TxA2 formation, a mediator of platelet aggregation59. Aspirin 
allergy, substituted by Clopidogrel 300mg stratum dose. 
 
 
  
REPERFUSION IN AMI:  
THROMBOLYSIS: 
            Thrombolytic therapy reduces the relative risk of in hospital death by 50 % 
when given in the first hour of onset of symptoms. 
Other uses  
¾ Limits infarct size 
¾ Limit LV dysfunction 
¾ Reduce the incidence of serious complications such as septal 
rupture, cardiogenic shock and malignant arrhythmias. 
       Benefit of thrombolysis possible upto 12 hrs, especially if chest discomfort is 
still present and ST segment remain elevated in ECG. 
       Goal of thrombolysis is to achieve – TIMI- grade 3, flow in the infarct related 
artery. 
 
 
 
 
 
  
ECG OF A PATIENT WITH ANTERIOR WALL MI 
 
DRUGS USED: 
¾ Streptokinase 
¾ Urokinase 
¾ t-PA – tissue plasminogen activator 
¾ APSAC 
¾ r-PA – recombinant staphylokinase 
¾ TNK- tPA – TNK variant of tissue plasminogen activator 
¾ Lanatoplase 
  
 t-PA is more effective than SK in restoring full perfusion ( TIMI- grade 3 flow)  
¾ SK – administered in 1.5 million units in a period of 1 hour. 
¾ t-PA – 15 mg bolus followed by 50mg IV, over the first 30 minutes, 
followed by 35 mg over next 15 minutes. 
¾  Reteplase – double bolus regimen of 10 MU bolus over 2- 3 
minutes followed by second 10 MU bolus, 30 minutes later. 
Mode of action – conversion of plasminogen to plasmin, which subsequently lyses 
fibrin thrombi.            
CRITERIA FOR THROMBOLYSIS: 
¾ Chest pain consistent with angina 
¾ ECG changes   
      ST ↑ ⊇ 1mm, ⊇ 2 contiguous limb leads. 
      ST ↑ ⊇ 2mm, ⊇ 2 contiguous precordial leads. 
      New onset LBBB. 
¾ Absence of contra-indications.        
 
 
 
  
CONTRA-INDICATIONS:   
ABSOLUTE: 
¾ Active internal bleeding 
¾ Suspected Aortic dissection 
¾ History of Hemorrhagic cerebrovascular accident or recent non-
hemorrhagic C.V.A. 
¾ Recorded B.P. > 200/120 
¾ Trauma or surgery that is a potential bleeding source within previous 2 
weeks. 
¾ Intracranial neoplasm or recent head trauma. 
RELATIVE CONTRA-INDICATIONS: 
¾ Prolonged , traumatic CPR 
¾ H/O non-hemorrhagic CVA in distant past 
¾ Recent trauma or surgery > 2 weeks previously 
¾ Active peptic ulcer disease 
¾ History of severe Hypertension with DBP >100 
¾ Bleeding diathesis or concurrent use of anticoagulants. 
¾ Pregnancy 
 
 
  
COMPLICATIONS:  
¾ Allergic reactions common with SK in 2 % of patients. Minor 
degrees of hypotension in 4 – 10 % of patients. 
¾ Hemorrhagic stroke is the most serious complication in 
approximately 0.5 – 0.9 % of patients more with age > 70 years.( 
Hemorrhage with t-PA  higher than SK). 
ASSESSMENT OF ADEQUACY OF THROMBOLYSIS: 
¾ Resolution of chest pain 
¾ ST segment resolution in ECG > 50% 
¾ Enzyme kinetics. 
¾ Troponin T or CK-MB mars – post / pre thrombolysis ratio > 5 at 6 
minutes >10 at 90 minutes. 
¾ Myocardial contrast Echocardiography. 
 
 
OTHER MODALITIES OF REPERFUSION: 
¾ Primary PTCA – with or without stenting. 
¾ Rescue angioplasty of failure of reperfusion beyond 90 minutes of 
thrombolysis. 
¾ Elective PCI in coronary artery re-occlusion or recurrent ischemia. 
  
ANTIPLATELET DRUGS: 
GOALS: 
¾ To establish and maintain patency of infarct-related artery 
¾ To reduce the patients tendency to thrombosis and thus the 
likelihood of mural thrombus formation or deep venous thrombus. 
DRUGS: 
1. UFH – Unfractionized Heparin. Useful in facilitating 
thrombolysis and establish patency of IRA in t-PA regimen 
of thrombolysis. Not so useful in SK regimen. 
Dose   -    Bolus 60U/kg 
                  Maintenance of 12 U/ kg /hr 
                  To keep aPTT – 1.5 to 2 times the control value. 
2. LMWH – Low molecular weight Heparins. 
Advantage over UFH due to increased anti-factor Xa: IIa ratio, 
decreased sensitivity to platelet factor IV, as more stable and 
reliable anticoagulant effect, enhanced bio-availability.  
No need for aPTT monitoring. 
 
  
DRUGS USED:  
        Nadroparin          } efficacy similar to UFH 
         Dalteparin           } efficacy similar to UFH 
         Enoxaparin           superior to UFH 
[ Enoxaparin 1 mg/ kg subcutaneous every 12 hrs] 
GPIIb / IIIa RECEPTOR INHIBITORS: 
      Facilitates thrombolysis and reduce rate of reocclusion of reperfused vessels. 
         Mode of action: Block the GP IIb / IIIa receptors of platelets surface which are 
the final common pathway in platelet aggregation. 
DRUGS: 
¾ Abciximab 
¾ Tirofiban 
¾ Eptifibatide 
More useful in NSTEMI. 
OTHER DRUGS: 
1. ACE inhibitors – should be prescribed within 24 hrs of AMI 
to all patients with MI and overt CHF. Reduction in 
  
ventricular remodeling after infarction with subsequent 
reduction in CHF. 
2. GIK infusion -  Glucose – Insulin – Potassium lower 
concentration of free fatty acids and improves ventricular 
performance. DOSE: 100 grams of glucose with 20 units of 
plain insulin and 50 mmol of potassium in 1 litre of water at 
a rate of 1.5 ml / kg / hr. 
3. Magnesium – minimize risk of arrhythmias in high risk 
patients with MI. 
 
 
COMPLICATIONS OF AMI:  
MECHANICAL COMPLICATIONS: 
VENTRICULAR DYSFUNCTION: 
         After AMI LV undergoes a series of changes in shape, size and thickness in 
both infarcted and non-infarcted segments, referred to as “ventricular remodeling” , 
precedes the development of CHF in the months to years after infarction. 
        Prevention by ACE inhibitors and other vasodilators like nitrates. 
 
 
  
CARDIOGENIC SHOCK: 
¾ Most common cause of in-hospital death with myocardial infarction. 
¾ Occurs within hours of onset of infarction due to massive ischemia and 
necrosis. 
¾ Occurs when 40 % or more of LV is destroyed. Mortality is > 80 %. 
CHARACTERISTICS: 
¾ Evidence of organ hypo perfusion – cold clammy skin and extremities, 
oliguria, decreased mentation. 
¾ SBP < 80 – 90 mm Hg 
¾ LVED pressure > 18 mm Hg 
¾ Cardic index < 1.8 L / M2 
REVERSIBLE CAUSES IN CRDIOGENIC SHOCK: 
 RVMI, mitral valve rupture, VSR, pulmonary embolism, cardiac tamponade. 
 Therapy: Dopamine, Dobutamine, Aortic counter pulsation, Mechanical 
reperfusion. 
MITRAL REGURGITATION: 
PAPILLARY MUSCLE DYSFUNCTION: 
     Posteromedial papillary muscle is involved in ischemia / infarction more 
commonly than anterolateral, since it is supplied predominantly by circumflex artery, 
whereas later receives dual blood supply. 
  
         Presents with sudden onset of apical systolic murmur. Papillary muscle rupture 
may complicate usually 2 – 7 days after acute MI. Presents as abrupt onset of 
pulmonary edema, harsh murmur but thrill is unusual. More common in inferior 
infarct. 
 
VENTRICULAR SEPTAL RUPTURE: 
9 1 – 3 % of AMI is complicated by VSR  
9 Majority in the first week 
9 New harsh holosystolic murmur along the left sternal border with thrill 
and sudden clinical deterioration with hypotension and pulmonary 
congestion. 
9 Prompt surgical management is necessary. 
FREE WALL RUPTURE[CARDIORRHEXIS]: 
9 Occurs in the first week of MI 
9 First infarction, history of hypertension, no history of angina pectoris and 
relatively large Q wave infarct are associated with high incidence of 
cardiac rupture. 
9 Sudden loss of pulse, B.P., and consciousness while ECG continues to 
show sinus rhythmn[apparent EMD]. 
 
  
RIGHT VENTRICULAR INFARCTION: 
9 40 % of inferoposterior MI have RVMI 
9 Spectrum ranges from asymptomatic minimal involvement to major 
hemodynamic impairment. 
CLINICAL FINDING: 
       CLASSIC – Elevated JVP, systemic hypotension, absence of pulmonary 
congestion. Additional signs – Kussmaul’s sign, cannon A waves in JVP, RV S3 , S4 
, hepatojugular reflux, T.R. , pulsus paradoxus, right sided pleural effusion. 
ECG changes:   Diagnostic – ST segment elevation of 1 mm or more in V4R. 
 Other changes – decreasing magnitude ST ↑ in precordial leads. ST ↑ in V2 
which is 50% less than the magnitude of ST ↑ in aVF. Leftward shift of transition 
zones. 
 COMPLICATIONS:   AV block, right to left shunting, TR, cardiogenic shock, 
and ventricular arrhythmias. 
MANAGEMENT: 
9 Avoid vasodilators 
9 Fluid – 0.9 % NS 1 – 2 L in the first hour, followed by 100 to 200ml / hr 
to keep SBP- 100 mm Hg or pulmonary artery wedge pressure – 18 cm 
H2O. 
  
9 Inotropic therapy – Dobutamine ( more beneficial than Dopamine as it 
does not raise the pulmonary vascular resistance). 
9 Reperfusion 
9 Maintenance of AV synchrony. 
Other complications – Pulmonary embolism, systemic embolism and ventricular 
aneurysm. 
ECG OF A PATIENT WITH VENTRICULAR TACHYCARDIA 
 
ELECTRICAL COMPLICATIONS: 
Mechanism for arrhythmias  
¾ Autonomic nervous system imbalance 
¾ Electrolyte disturbances 
¾ Ischemia 
  
¾ Slowed conduction in the zones of ischemic myocardium. 
TACHYARRHYTHMIAS: 
 Ventricular arrhythmias: VPC’s, VT, VF, AIVR. 
 Ventricular tachycardia is more common in inferior wall MI complicated by 
RVMI. 
 Supraventricular arrhythmias – Sinus tachycardia is the most common 
arrhythmia. SVT, AF and flutter also occur. 
 Accelerated junctional rhythmn is more common with inferoposterior MI. 
BRADYARRHYTHMIAS:  
 Sinus bradycardia is more common with inferoposterior and RVMI. Managed 
by Atropine. Persistent bradycardia may need pacing. 
 AV blocks are particularly common with inferior infarct, attributed to ischemia 
and enhanced vagal activity. 
I degree block needs no treatment 
II degree block particularly high grade type II blocks may require pacing. 
 Complete heart blocks are common in inferior infarct and they are transient, get 
corrected with reperfusion. Intraventricular conduction abnormalities of which 
LBBB is more common. 
  
RISK STRATIFICATION AFTER AMI: 
Most important predictors of 30 day mortality [ Gusto I trial]60 
 Age 
 Systolic BP 
 Killip class 
 Heart rate 
 Infarct location 
Most important independent predictors of 6 month mortality[GISSI 2 Database]61 
 Ineligibility to perform predischarge exercise test 
 Clinical LV failure 
 LV dysfunction, defined as EF < 40 % 
 Electrical instability 
 Age > 70 yrs. 
 
 
 
 
 
 
  
 
MATERIALS AND METHODS 
 This study was conducted in the Intensive Coronary Care Unit at Thanjavur 
Medical College Hospital, Thanjavur, during the period from April 2006 to October 
2006. 
 One hundred patients of AMI admitted to intensive coronary care unit. 
 Both male and female patients were included in the study. 
 Both young and old were included in the study. 
100 age- and sex matched healthy individuals were included in the study. 
INCLUSION CRITERIA:  
 Patients with a diagnosis of AMI were included in this study. AMI was 
diagnosed on the basis of 
 History of typical chest pain lasting ⊇ 30 minutes 
 Unresponsive to nitrates and  
 The presence of ST segment elevation in the electrocardiogram of 0.1 mv in ⊇ 
2 limb leads or 0.2 mv in ⊇ 2 precordial leads. 
 
 
  
 EXCLUSION CRITERIA:      
  Patients were excluded from the study when  
 The admission electrocardiogram exhibited technical limitations for 
analysis of QT dispersion (< 8 evaluable leads) 
 Patients were in atrial fibrillation (AF) or flutter. 
 Had left or right bundle branch block. 
 Patients receiving long term medications with drugs influencing QT 
duration were also not considered for the study. 
METHODOLOGY:                      
         Routine history taking, physical examination and laboratory investigations 
were performed in all subjects. 
        Simultaneous 12-lead electrocardiogram was recorded on HEWLETT 
PACKARD page writer 100 at a paper speed of 25mm/s. QT dispersion was calculated 
in all the patients of AMI as described by Van de loo et al-2  on admission, and in those 
who survived, 24 hours after admission and at the time of discharge from ICCU. 
           QT dispersion was defined as the difference between the maximum and 
minimum QT interval measurements among all the measured 12 leads on the standard 
electrocardiogram-3 [QT d = QT max – QT min]. For analysis of QT dispersion, RR 
and QT interval were measured in as many of the 12 leads as possible. Each 
measurement was taken as the mean value of 2 to 3 consecutive RR and QT intervals. 
  
          Ventricular arrhythmias were analyzed and its relationship to QT dispersion 
was observed.          
 
 
 
     
 
 
 
 
 
 
 
 
  
OBSERVATIONS AND ANALYSIS 
        This study was done in the Intensive Care Unit of Thanjavur Medical College, 
Thanjavur during the period from April 2006 to October 2006. 
The study was a prospective one. 
Both male and female patients were taken for the study. 
BASELINE CHARACTERISTICS: 
            The present study consisted of 100 patients of Acute Myocardial Infarction and an 
equal number of age- and sex matched healthy individuals. The age of the healthy 
individuals ranged from 30 to 85 years with a mean of 50.66 ± 17.65 years. The age of 
patients with AMI ranged from 30 to 82 years with a mean of 55.46 ± 12.97 years. There 
were 86 males and 14 females in each group. Out of hundred patients of AMI,53       were 
having anterior wall AMI and 47 had inferior wall AMI. 
SEX DISTRIBUTION:  
SEX NUMBER PERCENTAGE 
MALE 86 86% 
FEMALE 14 14% 
TOTAL 100 100% 
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AGE: 
AGE NO.OF 
MALES 
% OF 
MALES 
NO. OF 
FEMALES 
% OF 
FEMALES  
TOTAL 
NO 
% 
30 - 
39 
12 14 - - 12 12 
40 -
49 
14 16 03 21.5 17 17 
50 – 
59 
23 27 06 43 29 29 
60 – 
69 
23 27 02 14 25 25 
70 - 
79 
13 15 03 21.5 16 16 
80 - 
89 
01 01 - - 1 1 
 
TYPE OF INFARCT: 
SEX ANTERIOR ANTERIOR  INFERIOR INFERIOR 
 NUMBER PERCENTAGE NUMBER PERCENTAGE 
MALE 50 94 36 77 
FEMALE 3 6 11 23 
QT DISPERSION AMONG AMI: 
  QT dispersion in AMI was found to be significantly higher 82.56 ± 19.30 ms than in 
normal individuals 32.96 ± 10.06 ms, p<0.001. QT dispersion in patients of AMI was found 
to be higher on admission 82.56 ± 19.30 ms and was found to decrease later in the course of 
disease 62.12 ± 18.52 ms, 24 hours after admission and at the time of discharge from ICCU 
after an average stay of 7 days 51.98 ± 16.74 ms. The difference observed was statistically 
significant p < 0.05. The value at the time of discharge 51.98 ±16.74 ms was still higher than 
  
normal 32.96 ± 10.06 ms and the difference was statistically significant p < 0.05. QT 
dispersion was significantly greater in patients with anterior wall MI 87.01 ± 18.16 ms than 
in those with inferior wall MI 77.53 ± 17.04 ms       ; p < 0.05. 
Type of infarct QT d (ms.) 
ANTERIOR 87.01 ± 18.16 
INFERIOR 77.53 ± 17.04 
QT DISPERSION AND ARRHYTHMIA: 
             Out of 100 patients of AMI, 49 developed ventricular arrhythmias. QT dispersion 
was significantly higher 98.77 ± 10.16 ms in 49 patients with ventricular arrhythmia than 51 
patients without ventricular arrhythmias 66.98 ± 16.28; p < 0.01.          36 patients had 
ventricular premature beats(VPB’s), 8 had ventricular tachycardia (VT) and 5 had 
ventricular fibrillation. QT dispersion was significantly higher in patients with VT/VF 
(124.61 ± 11.14 ms ) than those who had only VPB’s 89.44 ± 11.42 ; p < 0.01. 
SEX NO. WITH 
VPB’S 
NO. WITH VT NO. WITH VF 
MALE 25 5 1 
FEMALE 11 3 4 
QT DISPERSION AND THROMBOLYTIC THERAPY: 
      Out of 100 patients of AMI, 58 were thrombolysed with streptokinase and          42 
were not. No statistically significant difference was observed in QT dispersion in the two 
groups 51.75 ± 16.05 ms vs 52.28 ± 14.68 ms ; p > 0.05 at the time of discharge from ICCU. 
  
QT DISPERSION AND PROGNOSIS: 
    Out of 100 patients of AMI, 6 patients died. 5 died due to ventricular arrhythmias 
and 1died due to causes other than arrhythmia. QT dispersion was found to be significantly 
higher in those who died 133.33 ± 10.97 ms than in those who survived 79.31 ± 17.91 ms ; p 
< 0.05. QT dispersion was significantly higher in arrhythmic deaths   134.4 ± 8.06 ms than 
in those who had non-arrhythmic deaths 128 ms ; p < 0.05. 
AGE ADJUSTED MORTALITY RATES: 
AGE 
GROUP 
SEX NO.OF 
CASES 
DEATHS % OF 
DEATHS 
 
M 12 - - 30-39 
F - - - 
M 14 - - 40-49 
F 3 - - 
M 23 2 8 50-59 
F 6 1 16 
M 23 - - 60-69 
F 2 1 50 
M 13 1 7 70-79 
F 3 1 33 
M 1 - - 80-89 
F - - - 
  
 
DISCUSSION 
  The present prospectively designed study aimed to examine QT dispersion in 100 
patients of AMI and an equal number of age-and sex matched healthy individuals. 
QT DISPERSION IN NORMAL INDIVIDUALS:  
     In normal individuals a low QT dispersion was observed 32.96 ± 10.06 ms. similar 
values of QT dispersion have been reported earlier62-65. Somewhat higher values have been 
reported in few other studies66-68. The results obtained by non-invasive assessment of QT 
dispersion from the surface echocardiogram are further substantiated by data obtained from 
endocardial or epicardial catheter mapping69. Using this method, several studies have 
demonstrated regional differences in ventricular repolarisation times of 40 to 55 ms70-71. 
Extensive body surface mapping has also been used to assess disparities in ventricular 
repolarisation in healthy persons and has revealed difference in QT duration of upto 60 ms72. 
Taken together these findings suggest that a range of QT dispersion between 30 and 50 ms 
appears to represent the normal limits of this parameter.  
QT DISPERSION IN AMI:  
      QT dispersion in patients of AMI ranged from 40ms to 144ms with an average of 
82.56 ± 19.30 ms which was significantly higher p < 0.001 than in normal healthy 
individuals 32.96 ± 10.06 ms. Patients with MI may have an inhomogenous ventricular 
repolarisation process. In the setting of AMI, the interplay between ischemic living tissue 
and relatively depolarized dying tissue would create a complex transition period affecting 
  
QT interval dispersion. In early stage of AMI, increase in QT dispersion would be primarily 
due to local shortening of action potential. However within few hours prolongation of QT 
interval would become the dominant feature governing QT dispersion73. 
                   In AMI, QT dispersion was highest at the time of admission 82.56 ± 19.30 ms 
and was to decrease in the course of time, 62.12 ± 18.52 ms at 24 hrs after admission and 
51.98 ± 16.74 ms at the time of discharge. The difference observed was statistically 
significant p < 0.05. Glancy et al74 measured QTc dispersion on days 1,2,3 and 6 in 17 
patients with AMI. They found the maximal QTc dispersion in the electrocardiogram taken 
on day 3. However in a large study of 316 consecutive patients, Newby et al 75 could not 
find significant difference in QT dispersion assessed at admission or after 2 and 3 days. 
QT DISPERSION AND SITE OF INFARCT: 
           QT dispersion was significantly greater in anterior wall AMI 87.01 ± 18.16 ms             
than in inferior wall AMI 77.53 ± 17.04 ms ; p < 0.05. Similar observations have been made 
earlier66-68. However, Cowan et al76 did not observe any significant difference in QT 
dispersion with different territory MI. 
QT DISPERSION AND REPERFUSION THERAPY:  
 In essence, the determinant of increased QT dispersion during AMI are : speed of 
reperfusion, patency of the infarct related artery[IRA], and location of AMI. Quick 
restoration of blood in the IRA post-MI decreases QT dispersion. Studies have shown that 
post infarction patients with open arteries have a lower mortality rate than patients with 
closed arteries. Mortality rates as low as 2.5% have been reported in patients with patent 
  
arteries compared with 15% in patients with closed arteries77. Mechanisms proposed to 
account for the beneficial effects of early and late reperfusion on mortality have been 
reviewed by Gersh and Anderson78. 
            In the present study no statistically significant difference was noted in QT dispersion 
at the time of discharge from ICCU in those who received thrombolytic therapy 51.75 
±16.05 ms and those who did not 52.28 ± 14.68 ms ;p > 0.05. Some previous studies68  also 
showed significant reduction in QT dispersion while others reported no change in QT 
dispersion after thrombolytic therapy66,67. 
QT DISPERSION, VENTRICULAR ARRHYTHMIAS AND MORTALITY IN AMI:  
           In experimental investigations, electrodes placed several millimeters apart with a 
small field of view have measured regional disparities in repolarisation. Variation in 
ventricular recovery time is an important factor in experimental tachyarrhythmias. The usual 
site of abnormal dispersion from which arrhythmias occur is at border zone of the infarcted 
area79. 
           In the present study QT dispersion was significantly higher p < 0.01 in patients of 
AMI with ventricular arrhythmias 98.77 ± 10.16 ms than those without 66.98 ± 16.28 ms. 
QT dispersion was significantly higher p < 0.01 in those with VT/VF 124.61 ± 11.14 ms 
than in those with VPB’s 89.44 ± 11.42 ms. 
           It simply illustrates the gradual increase in the heterogeneity of ventricular recovery 
from normal subjects to patients with uncomplicated MI to those with serious ventricular 
arrhythmias. 
  
          In the present study, QT dispersion at admission  was high in patients with AMI who 
died than those who survived 133.33 ± 10.97 ms vs 79.31 ± 17.91 ms ;p < 0.05. QT 
dispersion at admission was higher in patients with AMI with arrhythmic death 134.4 ± 8.06 
ms than those who had non-arrhythmic death 128 ms p < 0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
CONCLUSION 
The conclusions derived from this study include 
 Mean QT dispersion is significantly increased after Acute Myocardial 
Infarction. 
 QT dispersion shows a dynamic decrease with time. 
 Mean QT dispersion levels are higher in patients with ventricular 
tachycardia and ventricular fibrillation compared to patients with Acute 
Myocardial Infarction without these arrhythmias. 
 The change in QT dispersion are dynamic, and it may serve as a non-
invasive marker of susceptibility to malignant ventricular arrhythmias. 
 Males outnumbered females in the study. 
 Incidence is higher in older age group more so in females. 
 Most of the patients had anterior wall infarction. 
 
 
 
 
 
 
  
SUMMARY 
         As medical technology advances the physician is increasingly faced with a 
bewildering array of technical, diagnostic and therapeutic options for the treatment 
of Acute Myocardial Infarction. It has become important that the clinician be able to 
choose wisely among these available options, especially in the setting of Myocardial 
Infarction, where every minute is vital. 
       AMI is associated with changes in the electrophysiological properties of the 
heart. By means of assessing QT dispersion from the surface electrocardiogram there 
is convincing evidence that in AMI, inhomogeneity in ventricular repolarisation is 
augmented. Some clinical observations also indicate that this increased disparity in 
repolarisation is directly accompanied by the occurrence of ventricular arrhythmias 
and may help identify patients at high risk of sudden death. QT dispersion challenges 
our current approaches to the electrocardiographic assessment of arrhythmic risk. It 
provides a potentially simple, cheap, non-invasive method of measuring underlying 
dispersion of recovery of ventricular excitability. 
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QT DISPERSION AND EARLY ARRHYTHMIC 
RISK IN AMI 
PROFORMA 
           Name:                                                     Age   :          Years.        Sex: Male/Female 
             Occupation:                                            I.P. no: 
             Address:                                                 D.O.A: 
                                                                            D.O.D:      
 
           DATE & TIME OF ONSET OF PAIN: 
             DATE & TIME OF ADMISSION: 
             SYMBTOMS:   CHEST PAIN /   DYSPNOEA /   SWEATING /   GIDDINESS 
             H/O DRUG INTAKE WHICH PROLONGS QT INTERVAL        
             FINAL DIAGNOSIS: 
 
             KILLIP CLASSIFICATION: I / II / III / IV  
               THROMBOLYSED    NOT THROMBOLYSED  
                 
                 
ELECTROCARDIOGRAPHIC FINDINGS: 
DATE / 
DAY  
ON ADMISSION  24 HRS LATER AT DISCHARGE 
RATE/MIN    
RHYTHM    
PR INTERVAL    
QRS DURATION    
ST SEGMENT    
T WAVE    
RR INTERVAL    
BLOCK      
ADMISSION DAY 2          AT DISCHARGE 
Pulse/min    
B.P. mmHg    
Basal crepts    
C.V.S.    
  
QT DISPERSION    
ARRHYTHMIA 
 
   
 
 ECHOCARDIOGRAPHIC FINDINGS: 
 
 CAHD-HYPOKINESIA OF ANTERIOR WALL 
                                               LOWER1/2 IVS 
                                               INFERIOR WALL 
                                               LVEF:     % 
 
 OUTCOME: ALIVE  DEATH   NO ARRHYTHMIA   ARRHYTHMIA- TYPE    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
MASTER CHART FOR HEALTHY CONTROLS  
 
 
S.NO NAME AGE SEX QT d (ms) 
1 YASHODHA 57 F 32 
2 SUBBULAXMI 60 F 20 
3 KARTHIKARANI 45 F 40 
4 HELEN MARY 35 F 20 
5 TAMILSELVI 40 F 32 
6 RAJAMMAL 40 F 32 
7 REITA 42 F 40 
8 CHINTHAMANI 58 F 32 
9 MOOKAYEE 65 F 40 
10 VASANTHA 60 F 24 
11 MAHALAXMI 63 F 44 
12 MALLIGA BEGUM 52 F 32 
13 AMSAVALLI 50 F 40 
14 AROOVAM 62 F 24 
15 NATARAJAN 60 M 40 
16 AYYA 72 M 48 
17 ASAI 75 M 36 
18 SUNDARESAN 57 M 20 
19 RAVI 31 M 32 
20 CHINARASU 45 M 44 
21 KARUPAIYAN 60 M 36 
22 MURUGESAN 35 M 20 
23 RAJAGOPAL 52 M 40 
24 PANNEERSELVAM 50 M 36 
25 KRISHNAMOORTHI 52 M 20 
26 RAJENDIRAN 30 M 20 
27 MURUGESAN 45 M 40 
28 JAGANATHAN 50 M 36 
29 RAMASAMY 63 M 48 
30 THANDAYUTHAPANI 50 M 24 
31 RAJENDIRAN 48 M 44 
32 NALLAIYAN 55 M 32 
33 KULANCHIAPPAN 40 M 40 
34 NARASIMHAN 30 M 44 
35 RAJA 30 M 20 
36 DHANAPAL 45 M 28 
37 CHANDIRAN 45 M 28 
38 RAJENDIRAN 35 M 40 
39 CHINNADURAI 32 M 44 
40 CHINNAIYAN 78 M 40 
41 KANNAN 67 M 24 
42 PARAMASIVAM 55 M 40 
43 VEERAMUTHU 56 M 36 
44 NARAYANAMOORTHI 30 M 44 
45 MANI 57 M 36 
46 PACKIRISAMY 58 M 20 
47 PARAMASIVAM 65 M 40 
48 KALYAN 40 M 24 
49 BASKARAN 57 M 48 
50 MANI 45 M 32 
51 SHANMUGAM 50 M 28 
  
52 THANGARAJ 35 M 24 
53 SELVARAJ 33 M 44 
54 ANBALAGAN 43 M 24 
55 RAMALINGAM 54 M 40 
56 SUBRAMANIAN 33 M 20 
57 THAVASI 45 M 32 
58 KRISHNAN 66 M 36 
59 GURUMOORTHI 45 M 24 
60 MANIVEL 54 M 20 
61 MARUTHAMUTHU 75 M 24 
62 RAMU 50 M 36 
63 RAMANATHAN 58 M 40 
64 PERIYASAMY 34 M 40 
65 RAJENDIRAN 39 M 24 
66 KARUNANITHI 53 M 24 
67 MURUGAIYAN 58 M 36 
68 PALANIYANDI 65 M 48 
69 KALIYAMOORTHI 55 M 36 
70 GANESAN 49 M 40 
71 LAKSHMAN 54 M 24 
72 MURUGESAN 45 M 36 
73 SHANKAR 35 M 44 
74 JEYAKUMAR 46 M 36 
75 SUNDARAMOORTHI 40 M 36 
76 RAMALINGAM 45 M 40 
77 RADHAKRISHNAN 40 M 44 
78 KANNAN 48 M 48 
79 DEVARAJ 43 M 40 
80 GUNASEKARAN 50 M 32 
81 MANICKAM 57 M 24 
82 ANTONY SAMY 38 M 40 
83 MD. ANIF 74 M 20 
84 THIYAGARAJAN 60 M 36 
85 PERIYASAMY 45 M 28 
86 RAVICHANDRAN 30 M 24 
87 SWAMINATHAN 63 M 36 
88 SHANMUGANATHAN 65 M 40 
89 RAVICHANDRAN 35 M 36 
90 PANDIYAN 56 M 20 
91 KRISHNAMOORTHI 43 M 28 
92 SATHYAMOORTHI 76 M 40 
93 KRISHNAMOORTHI 34 M 24 
94 SOUNDARAJAN 45 M 24 
95 RAJENDIREN 60 M 36 
96 SAMINATHAN 50 M 24 
97 SATHASIVAM 85 M 36 
98 DURAISAMY 70 M 24 
99 KULANTHAIVELU 60 M 20 
100 AROCKIASAMY 62 M 20 
 
 
 
  
     
